Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

Item

http://www.wikidata.org/entity/Q36801561

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

@ast

Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

@en

type

Item

label

Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

@ast

Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

@en

prefLabel

Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

@ast

Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

@en

P1476

Onco-nephrology: an appraisal of the cancer and chronic kidney disease links.

@en

P2093

Hassan Izzedine

http://www.w3.org/2001/XMLSchema#string

Mark A Perazella

http://www.w3.org/2001/XMLSchema#string

P2860

September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents

Erythropoietin as an adjuvant treatment with (chemo) radiation therapy for head and neck cancer

The erythropoietin receptor in normal and cancer tissues

Cancers of the kidney and urinary tract in patients on dialysis for end-stage renal disease: analysis of data from the United States, Europe, and Australia and New Zealand.

Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.

Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia.

Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.

Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes.

P304

1979-1988

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDT/GFU387

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272076402

http://www.w3.org/2001/XMLSchema#string

P698

25648910

http://www.w3.org/2001/XMLSchema#string

P932

4832985

http://www.w3.org/2001/XMLSchema#string